Navigation Links
A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
Date:11/25/2011

GOTHENBURG, Sweden, November 25, 2011 /PRNewswire/ --

Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala. At the same time, the company secures substantial financing to complete the clinical trial.

- It's a big and important step to test the vaccine on humans for the first time. Our animal studies have shown good results, so we feel safe to continue, says Jamal El-Mosleh, CEO of Immunicum.

Immunicum's patented cancer vaccine is based on over 20 years of research in the field of transplantation immunology and activates the body's own immune system to attack tumor cells. The Nobel Prize in Medicine was recently awarded the discoverer of dendritic cells and their role in immunological reactions, the same type of cells that Immunicum bases its vaccines on.

- However, our vaccines differ from other cancer vaccines. Traditionally, dendritic cell-based cancer vaccines are made from patients' own cells. This means that each vaccine must be specially made for each patient, which is expensive, complex and takes time. Moreover, it is physically stressful for the patient who is seriously ill, says Jamal El-Mosleh.

Immunicum's vaccine is based on using dendritic cells from healthy individuals and can thus be mass-produced, leading to significant commercial advantages.

The vaccine has been tested in animal studies to examine its therapeutic effect and tumors were reduced in both weight and volume. Toxicity studies have also been conducted to investigate possible side effects, especially with a focus on autoimmune diseases. The study showed no evidence of adverse side effects.

Through the green light from the Medical Products Agency, a clinical phase I/II trial will be initiated within the next few months on twelve patients with metastatic renal
'/>"/>

SOURCE Immunicum
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
2. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
3. Cell-based alternative to animal testing
4. Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
5. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
6. O2h and Hypoxium Announce an Agreement to Offer Hypoxiums Specialised In Vitro, Cell-Based Oncology Assays via O2hs Biology Affiliate Program
7. Stemgent, CellDesign Sign Co-Exclusive Marketing Agreement on Stem Cell-Based Adipocyte Research Products
8. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
9. MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery
10. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
11. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 Today, Nerium International, ... the winners of its “Reflect Your Youth” contest, an ... only seen a difference in their skin since using ... new outlook on life as a result of their ... as an effort by Nerium International to inspire conversations ...
(Date:10/25/2014)... Durham, NC (PRWEB) October 24, 2014 ... appears to overcome several pitfalls of current skin grafting ... scarring and produces hair. The method, outlined in the ... a breakthrough for treating deep skin injuries that result ... skin injury completely destroys the skin’s regenerative elements. These ...
(Date:10/25/2014)... October 24, 2014 Oramed Pharmaceuticals ... company focused on the development of oral drug delivery ... Kidron will present at FireRock Capital,s Micro-Cap Conference. ... Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: 9:15am ... New York City , About ...
(Date:10/25/2014)... Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the ... the Fourth International Symposium on Thymosins in Health and ... "When thymosin beta 4 (TB4) linked with ... peritoneal cavity in a rodent model of stroke, it ... brain parenchyma (the functional tissue of the brain).   The ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... Wash., June 16, 2011 SCOLR Pharma, Inc. (OTC: ... of $1 million principal amount of its 8% Senior ... initial closing of its private offering of up to ... offer additional Debentures, up to the aggregate maximum of ...
... KNDL ), a leading, global full-service ... senior clinical development experts will present on important ... 47th Annual Meeting, June 19-23, 2011, in Chicago. ... benefits of hybrid monitoring; finding an economic balance ...
... 2011 MacuCLEAR, Inc., a specialty clinical stage pharmaceutical ... vascular disorders of the eye, announced today that Philip ... OneMedForum New York 2011 on Thursday, June 23, 2011 ... New York City.   OneMedForum will focus ...
Cached Biology Technology:SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 2SCOLR Pharma, Inc. Announces Initial Closing of Private Placement 3Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 2Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 3MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C. 2
(Date:10/19/2014)... Improving household electricity access in India over the ... nation,s total carbon emissions growth during that time, ... journal Nature Climate Change ., "Energy access ... all aspects of life, including education, communication, and ... the study. , While increased energy access is ...
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... found a way of stimulating the immune systems ... the devastating plaques,that are characteristic of Alzheimer's disease.,For ... a,protein-based vaccine to slow the progression of the ... created a gene-based,vaccine aimed at stimulating the immune ...
... cells',responsible for hearing and balance. Traditionally viewed as ... for the normal development,of nerve cells responsible for ... research. The study is reported in the January ... scientists at the University,of Washington.,"Using zebrafish as a ...
... essential for 'hair cells',responsible for hearing and balance. ... may be essential for the normal development,of nerve ... new,University of Utah research. The study is reported ... is co-authored by scientists at the University,of Washington.,"Using ...
Cached Biology News:Gene vaccine for Alzheimer's disease shows promising results 2GenMAPP 2.0 released 2Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined 2
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... macroporous polystyrene beads for hydrophobic interaction chromatography. ... adsorbing organics of molecular weight less than ... useful for the adsorption of nonpolar substances ... removal of detergents such as Triton X-100 ...
... : Fusion protein corresponding to ... human Mi-2 Formulation: 0.7M Tris-glycine, ... sodium azide, containing 30% glycerol ... immunoblot on Hela nuclear extract ...
... Phospho-Specific(Thr 222 ) ... 10 mM sodium HEPES, 100 ... 7.5. Recognizes the ~47 kDa ... (MAPKAPK-2) protein phosphorylated at Thr ...
Biology Products: